The biological rationale behind SCR-A008 rests on a careful exploitation of a molecular difference between tumors and healthy tissue. CDH17 is highly expressed in gastric cancer tissues but shows limited expression in normal tissues, a selectivity profile that makes it an attractive docking site for a targeted cytotoxic payload. Antibody-drug conjugates, often described as guided missiles of oncology, couple an antibody that recognizes a specific tumor antigen to a potent cell-killing drug through a chemical linker. When the antibody binds its target on the cancer cell surface and the complex is internalized, the payload is released inside the tumor, ideally sparing healthy cells from collateral damage. By choosing CDH17 as the target, the researchers aimed to concentrate lethal chemotherapy-like activity precisely where it is needed most.

To test the compound in a setting that faithfully mirrors human disease, the team turned to patient-derived xenografts, or PDX models, in which fragments of a patient’s tumor are implanted into mice and grown while retaining the original tumor’s molecular characteristics. From a bank of 59 PDX models, the investigators used immunohistochemistry to select one with moderate CDH17 expression, deliberately avoiding the temptation to test only in models with the highest target levels. This choice matters: a drug that works even when its target is only moderately abundant is more likely to help the broad population of patients whose tumors do not overexpress a marker dramatically. The selected model became the testing ground for SCR-A008 both as a single agent and in combination with chemotherapy.

The monotherapy results were striking. A single administration of SCR-A008 produced sustained tumor inhibition across various doses, an unusually durable effect for a single treatment in a PDX setting. Sustained suppression after one dose suggests that the conjugate delivers its payload efficiently and that the resulting tumor cell death is not quickly reversed by regrowth, a common problem with conventional cytotoxic drugs that require repeated cycles. Based on the dose-response data, the researchers selected 1 mg/kg as the dosage for subsequent combination studies, a decision that balanced efficacy against tolerability and set the stage for the most clinically relevant experiments of the study.

When SCR-A008 was combined with paclitaxel, one of the workhorse chemotherapy drugs used against gastric cancer, the results exceeded what either drug achieved alone. At 42 days after treatment, the combination achieved a tumor growth inhibition, or TGI, of 95 percent. That figure stood well above the 86 percent TGI seen with SCR-A008 monotherapy, the 61 percent achieved by paclitaxel alone, and the 47 percent produced by the standard combination of 5-fluorouracil with oxaliplatin, a regimen representing current chemotherapy practice. In other words, the targeted conjugate did not merely add to chemotherapy; it transformed the outcome in this model, nearly halting tumor growth for the duration of the observation period.

A critical question for any combination strategy is whether the two drugs interfere with each other’s movement through the body. To address this, the team characterized the pharmacokinetics of SCR-A008 using both a total antibody assay, referred to as a TAA assay, and an ADC-specific assay, which together capture how the intact conjugate and its antibody component circulate and clear over time. Notably, the pharmacokinetic profiles showed no significant differences between SCR-A008 given as a single drug and SCR-A008 given alongside chemotherapy. This absence of pharmacokinetic interaction is an important green light for combination development, indicating that paclitaxel does not accelerate the clearance of the conjugate or otherwise disrupt its exposure, so the two agents can be expected to behave in patients much as they do individually.

Beyond measuring tumor size, the researchers probed the biology inside the treated tumors by assessing pharmacodynamic biomarkers with immunohistochemistry. The SCR-A008 plus paclitaxel group exhibited significantly elevated expression of phosphorylated ERK, or p-ERK, along with relatively higher levels of phosphorylated NBS1 at 336 hours after treatment. These molecular readouts provide clues about how tumor cells respond to the combined assault: p-ERK activation can reflect signaling changes triggered by cellular stress and DNA-damaging pressure, while p-NBS1 is a marker of DNA damage response machinery being recruited. Elevated levels of such markers in the combination group are consistent with the idea that the ADC payload and the taxane chemotherapy converge on tumor cells in ways that overwhelm their survival and repair programs.

The study also touched on the practical challenge of translating biomarker assessment into clinical use. The investigators evaluated the concordance between AI-based scoring and manual pathologist-based scoring of CDH17 expression, an increasingly relevant issue as diagnostic laboratories consider automated image analysis for patient selection. Reliable, reproducible measurement of target expression is essential if a CDH17-targeted therapy is to reach the right patients, and the comparison of machine scoring with expert pathologist readings speaks directly to the infrastructure that would be needed in a clinical trial or, eventually, routine practice.

The significance of this work lies in the population it aims to serve. Patients whose tumors are pMMR/MSS, HER2-low or HER2-negative, or who have developed resistance to HER2-targeted agents, currently have limited options beyond conventional chemotherapy, which often delivers modest benefit at considerable toxicity. A CDH17-directed ADC could offer a new line of attack for precisely these groups, and the demonstration of activity in a model with only moderate target expression widens the potential patient pool further. The authors conclude that the study provides vital insights into the efficacy and safety of SCR-A008 and may potentially address a significant unmet medical need in gastric cancer, a disease that remains a leading cause of cancer-related deaths worldwide.

As with all preclinical research, the path from a PDX model to an approved medicine requires careful clinical testing, and the present findings represent an early but meaningful step. The durability of response after a single dose, the strong performance of the paclitaxel combination, the clean pharmacokinetic interaction profile, and the mechanistic biomarker data together form a coherent package supporting further development of SCR-A008. If the selectivity of CDH17 expression observed in tumors versus normal tissues holds true in patients, this conjugate could join the growing class of antibody-drug conjugates that are reshaping treatment for hard-to-treat cancers, offering new hope where chemotherapy alone has long fallen short.

Subject of Research: Preclinical evaluation of the CDH17-targeted antibody-drug conjugate SCR-A008 in gastric cancer patient-derived xenograft models

Article Title: SCR-A008, a novel CDH17-targeted ADC, exhibited potent tumor inhibition in CDH17-positive gastric cancer PDX model

Article References: Guo, T., An, G., Li, H., Ji, X., Hu, Y., Zhong, F., Ao, C., Yan, S., Zhang, W., Mei, W., Bi, J., Li, C., Chen, L., Fu, Y., Cheng, G., Guo, H., Yang, C., Tang, R., Wang, X., … Ji, J. (2026). SCR-A008, a novel CDH17-targeted ADC, exhibited potent tumor inhibition in CDH17-positive gastric cancer PDX model. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08895-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08895-4

Keywords: gastric cancer, CDH17, antibody-drug conjugate, SCR-A008, patient-derived xenograft, paclitaxel, pharmacokinetics, biomarker, targeted therapy, tumor growth inhibition, p-ERK, immunohistochemistry